GlassScriptPhysician profile
Todd A Zelczak
NPI 1922195775
$14,990.16
in general payments reported to CMS, 2019-2025
29 companies · $3,996 in 2025
The $3,996 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,523 · 2020: $2,238 · 2021: $1,090 · 2022: $1,157 · 2023: $1,145 · 2024: $2,842 · 2025: $3,996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,783 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,783.09 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $4,258.82 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $2,212.29 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $1,626.42 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $1,173.50 | 2019-2025 | Cequa, Xelpros |
| Oyster Point Pharma, INC. | $784.24 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $779.35 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $619.67 | 2019-2023 | |
| Visioneering Technologies, INC. | $603.53 | 2025 | |
| Abbvie INC. | $378.31 | 2022-2025 | Durysta, Alphagan P, Vuity |
| Shire North American Group INC | $317.09 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $314.67 | 2019-2021 | |
| Alcon Vision LLC | $282.72 | 2019-2025 | Precision7, Tryptyr, Rocklatan |
| Kala Pharmaceuticals, INC. | $272.29 | 2021-2022 | |
| Thea Pharma INC. | $197.07 | 2023-2025 | Iyuzeh |
| Johnson & Johnson Vision Care, INC. | $186.29 | 2019-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $175.57 | 2020-2024 | Oxervate |
| Harrow Eye, LLC | $175.42 | 2024-2025 | Vevye |
| Ivantis, INC | $142.59 | 2021 | |
| Eyevance Pharmaceuticals LLC | $85.64 | 2019-2022 | |
| Biotissue Holdings INC. | $80.34 | 2022-2025 | |
| Coopervision INC. | $71.15 | 2019-2025 | Myday Contact Lens |
| Horizon Therapeutics Plc | $65.73 | 2021-2023 | Tepezza |
| Glaukos Corporation | $62.42 | 2024 | |
| Ocular Therapeutix, INC. | $47.34 | 2022-2024 | Dextenza |
| Mallinckrodt Enterprises LLC | $21.38 | 2019 | |
| Sight Sciences, INC. | $15.83 | 2022 | |
| Amgen INC. | $14.96 | 2025 | Tepezza |
| Akorn, INC. | $12.84 | 2020 | |
| Lkc Technologies, INC. | $12.69 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Zelczak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.